<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="cam46801" xml:lang="en" article-type="brief-report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Med</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id><journal-id journal-id-type="pmc-domain-id">1974</journal-id><journal-id journal-id-type="pmc-domain">canmed</journal-id><journal-id journal-id-type="publisher-id">CAM4</journal-id><journal-title-group><journal-title>Cancer Medicine</journal-title></journal-title-group><issn pub-type="epub">2045-7634</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10757126</article-id><article-id pub-id-type="pmcid-ver">PMC10757126.1</article-id><article-id pub-id-type="pmcaid">10757126</article-id><article-id pub-id-type="pmcaiid">10757126</article-id><article-id pub-id-type="pmid">38070180</article-id><article-id pub-id-type="doi">10.1002/cam4.6801</article-id><article-id pub-id-type="publisher-id">CAM46801</article-id><article-id pub-id-type="other">CAM4-2023-08-3811.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Brief Communication</subject></subj-group><subj-group subj-group-type="heading"><subject>BRIEF COMMUNICATION</subject><subj-group subj-group-type="heading"><subject>Clinical Cancer Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Utilization of cardiac tests in anthracycline&#8208;treated cancer survivors differs between young adults and children: A claims&#8208;based analysis</article-title><alt-title alt-title-type="left-running-head">Ji et&#160;al.</alt-title></title-group><contrib-group><contrib id="cam46801-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Ji</surname><given-names initials="X">Xu</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3025-3984</contrib-id><xref rid="cam46801-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cam46801-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>xu.ji@emory.edu</email></address></contrib><contrib id="cam46801-cr-0002" contrib-type="author"><name name-style="western"><surname>Hu</surname><given-names initials="X">Xin</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1097-3300</contrib-id><xref rid="cam46801-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cam46801-cr-0003" contrib-type="author"><name name-style="western"><surname>Lipscomb</surname><given-names initials="J">Joseph</given-names></name><xref rid="cam46801-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="cam46801-cr-0004" contrib-type="author"><name name-style="western"><surname>Chow</surname><given-names initials="EJ">Eric J.</given-names></name><xref rid="cam46801-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cam46801-cr-0005" contrib-type="author"><name name-style="western"><surname>Mertens</surname><given-names initials="AC">Ann C.</given-names></name><xref rid="cam46801-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cam46801-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cam46801-cr-0006" contrib-type="author"><name name-style="western"><surname>Castellino</surname><given-names initials="SM">Sharon M.</given-names></name><xref rid="cam46801-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cam46801-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="cam46801-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Pediatrics</named-content>
<institution>Emory University School of Medicine</institution>
<city>Atlanta</city>
<named-content content-type="country-part">Georgia</named-content>
<country country="US">USA</country>
</aff><aff id="cam46801-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Aflac Cancer &amp; Blood Disorders Center, Children's Healthcare of Atlanta</institution>
<city>Atlanta</city>
<named-content content-type="country-part">Georgia</named-content>
<country country="US">USA</country>
</aff><aff id="cam46801-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Public Health Sciences</named-content>
<institution>University of Virginia School of Medicine</institution>
<city>Charlottesville</city>
<named-content content-type="country-part">Virginia</named-content>
<country country="US">USA</country>
</aff><aff id="cam46801-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Health Policy and Management, Rollins School of Public Health</named-content>
<institution>Emory University</institution>
<city>Atlanta</city>
<named-content content-type="country-part">Georgia</named-content>
<country country="US">USA</country>
</aff><aff id="cam46801-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>University of Washington School of Medicine and Fred Hutchinson Cancer Research Center</institution>
<city>Seattle</city>
<named-content content-type="country-part">Washington</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Xu Ji, Department of Pediatrics, Emory University School of Medicine, 2015 Uppergate Dr, Atlanta, GA 30322, USA.<break/>
Email: <email>xu.ji@emory.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2023</year></pub-date><volume>12</volume><issue seq="410">24</issue><issue-id pub-id-type="pmc-issue-id">451924</issue-id><issue-id pub-id-type="doi">10.1002/cam4.v12.24</issue-id><fpage>22056</fpage><lpage>22061</lpage><history><date date-type="rev-recd"><day>01</day><month>11</month><year>2023</year></date><date date-type="received"><day>05</day><month>8</month><year>2023</year></date><date date-type="accepted"><day>28</day><month>11</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>09</day><month>12</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>31</day><month>12</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-01-29 19:25:22.077"><day>29</day><month>01</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2023 The Authors. <italic toggle="yes">Cancer Medicine</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CAM4-12-22056.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CAM4-12-22056.pdf"/><abstract><title>Abstract</title><sec id="cam46801-sec-1001"><title>Background</title><p>The Children's Oncology Group Guidelines recommend a cardiacechocardiogram, or comparable functional imaging, following therapy completion in survivors of childhood/adolescent cancers exposed to anthracyclines.</p></sec><sec id="cam46801-sec-1002"><title>Methods</title><p>Using the 2009&#8211;2019&#8201;Merative&#8482; MarketScan&#174; Commercial Database, we examined real&#8208;world utilization of cardiac testing among 1609 anthracycline&#8208;treated survivors of childhood/adolescent cancers.</p></sec><sec id="cam46801-sec-1003"><title>Results</title><p>The cumulative incidence of receiving an initial cardiac test by 5.25&#8201;years from the index date (six months after end&#8208;of&#8208;therapy) was 62.3% (95% CI&#8201;=&#8201;57.5%&#8211;66.7%), with median time to initial test being 2.7&#8201;years (95% CI&#8201;=&#8201;2.5%&#8211;3.1%). Young adults (18&#8211;28&#8201;years) were less likely than children (&#8804;17&#8201;years) to receive cardiac testing (hazard ratio [HR]&#8201;=&#8201;0.42, 95% CI&#8201;=&#8201;0.3%&#8211;0.49%). More likely to receive cardiac testing were survivors receiving hematopoietic stem cell transplantation versus chemotherapy only (HR&#8201;=&#8201;2.23, 95% CI&#8201;=&#8201;1.63%&#8211;3.03%), and survivors with bone or soft tissue versus hematologic cancer (HR&#8201;=&#8201;1.64, 95% CI&#8201;=&#8201;1.30%&#8211;2.07%).</p></sec><sec id="cam46801-sec-1004"><title>Conclusions</title><p>Nearly 40% of anthracycline&#8208;treated survivors of childhood/adolescent cancers had not received cardiac testing within 5.25&#8201;years post&#8208;index date, with young adults least likely to receive a test.</p></sec></abstract><abstract abstract-type="graphical"><p>In this nationwide, insurance claims data&#8208;based study, we examined the real&#8208;world utilization of cardiac tests after therapy completion among anthracycline&#8208;treated survivors of childhood and adolescent cancer. We found that nearly 40% of anthracycline&#8208;treated survivors at risk of cardiac dysfunction had not received any cardiac test within 5.25&#8201;years from 6&#8201;months after end&#8208;of&#8208;therapy, despite national guidelines detailing the importance of timely screening for early detection of cardiac dysfunction. Young adult survivors were least likely to receive cardiac testing despite having insurance.<boxed-text position="anchor" content-type="graphic" id="cam46801-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CAM4-12-22056-g002.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cam46801-kwd-0001">anthracycline</kwd><kwd id="cam46801-kwd-0002">cardiac testing</kwd><kwd id="cam46801-kwd-0003">commercial claims data</kwd><kwd id="cam46801-kwd-0004">survivors of childhood and adolescent cancer</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Centers for Disease Control and Prevention
</institution><institution-id institution-id-type="doi">10.13039/100000030</institution-id></institution-wrap></funding-source><award-id>SIP20&#8208;004</award-id></award-group><award-group id="funding-0002"><funding-source>Pediatric Research Alliance and Children's Healthcare of Atlanta</funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="1"/><page-count count="6"/><word-count count="3349"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2023</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.6 mode:remove_FC converted:30.12.2023</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="CAM46801-cit-2001"><string-name name-style="western"><surname>Ji</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lipscomb</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chow</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Mertens</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Castellino</surname><given-names>SM</given-names></string-name>. <article-title>Utilization of cardiac tests in anthracycline&#8208;treated cancer survivors differs between young adults and children: A claims&#8208;based analysis</article-title>. <source>Cancer Med</source>. <year>2023</year>;<volume>12</volume>:<fpage>22056</fpage>&#8208;<lpage>22061</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cam4.6801</pub-id><pub-id pub-id-type="pmcid">PMC10757126</pub-id><pub-id pub-id-type="pmid">38070180</pub-id></mixed-citation>
</p></notes></front><body id="cam46801-body-0001"><sec id="cam46801-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Survivors of childhood and adolescent cancer exceed 500,000 in the United States, and this population continues to grow.<xref rid="cam46801-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Survivorship guidelines recommend screening for cardiotoxicity associated with therapeutic exposure in childhood and adolescent malignancies.<xref rid="cam46801-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="cam46801-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="cam46801-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> Specifically, the Children's Oncology Group (COG) Guidelines recommend a cardiac echocardiogram, or comparable functional imaging, following therapy completion in survivors exposed to anthracyclines.<xref rid="cam46801-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> There is currently a dearth of evidence on posttreatment uptake of guideline&#8208;recommended cardiac testing in exposed survivors. Existing studies used self&#8208;report data, focused on clinical trial settings, or else were not United States&#8208;based.<xref rid="cam46801-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="cam46801-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="cam46801-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Using nationwide insurance claims data, we examined real&#8208;world utilization of cardiac testing following therapy completion among anthracycline&#8208;treated survivors of childhood and adolescent cancers.</p></sec><sec sec-type="methods" id="cam46801-sec-0002"><label>2</label><title>METHODS</title><p>We used the 2009&#8211;2019 Merative&#8482; MarketScan&#174; Commercial Database, a nationwide convenience sample of outpatient, inpatient, and pharmacy insurance claims from United States employer&#8208;sponsored health plans.<xref rid="cam46801-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="cam46801-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> We identified survivors who (a) received anthracyclines for hematologic cancers or bone and soft tissue cancers (aged &#8804;21&#8201;years at cancer diagnosis; Table&#160;<xref rid="cam46801-supitem-0001" ref-type="supplementary-material">S1</xref>); (b) completed cancer therapies; and (c) remained continuously insured for &#8805;1&#8201;year from their index date, defined as 6&#8201;months after the end&#8208;of&#8208;therapy date (Figure&#160;<xref rid="cam46801-supitem-0001" ref-type="supplementary-material">S1</xref>). In a sensitivity analysis that modified the definition of index date to the end&#8208;of&#8208;therapy date, we found similar results (available upon request). End&#8208;of&#8208;therapy refers to 30&#8201;days following either the last date of inpatient or outpatient claims for cancer therapies or the date when the last oral chemotherapy prescription is filled, whichever is later.<xref rid="cam46801-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="cam46801-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="cam46801-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> We followed the algorithm applied in previous claims data&#8208;based studies to identify hematologic cancers and bone and soft tissue cancers,<xref rid="cam46801-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="cam46801-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="cam46801-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> which represent the majority of anthracycline&#8208;treated childhood and adolescent cancers.<xref rid="cam46801-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Specifically, cancer diagnoses were identified using the International Classification of Diseases (ICD) codes, and cancer therapies (surgery, chemotherapy, radiotherapy, and hematopoietic stem cell transplantation) were identified using procedure codes and the National Drug Codes.<xref rid="cam46801-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="cam46801-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="cam46801-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</p><p>We used the Kaplan&#8211;Meier method to estimate the cumulative incidence of receipt of the first cardiac test&#8212;including echocardiogram, cardiac magnetic resonance imaging, and/or multiple gate acquisition scan (Table&#160;<xref rid="cam46801-supitem-0001" ref-type="supplementary-material">S2</xref>)&#8212;within 5.25&#8201;years post index date, allowing a leeway of 0.25&#8201;year (3&#8201;months) for potential delays in scheduling medical appointments as the 5&#8208;year cut&#8208;point for adherence approaches. Censoring occurred at the end of a year if survivors discontinued insurance enrollment in the following year, or at the end of our study period (December 31, 2019). Cumulative incidence curves were generated for all survivors, as well as among subgroups stratified by key sociodemographic characteristics that may contribute to differential utilization of cardiac tests.</p><p>Cox proportional hazards regressions were used to identify survivor characteristics that were significantly associated with the first cardiac test receipt occurring within 5.25&#8201;years post index date, applying the same censoring approach as described above. The regression models adjusted for survivors' sociodemographic characteristics (age at index, sex, region, rurality, health plan type, year of index date) and clinical factors (cancer type, treatment modality) individually (unadjusted analysis), and then combined (multivariable analysis). The proportional hazards assumption of the Cox model was tested using cumulative sums of martingale&#8208;based residuals developed by Lin et&#160;al.<xref rid="cam46801-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> and no violation was detected.</p></sec><sec sec-type="results" id="cam46801-sec-0003"><label>3</label><title>RESULTS</title><p>We identified 1609 survivors treated with anthracyclines during childhood and adolescence; 48.4% had attained young adult age (18&#8211;28&#8201;years) at index date, 47.4% were female, and 13.1% were residing in rural areas (Table&#160;<xref rid="cam46801-tbl-0001" ref-type="table">1</xref>). The majority of our sample were diagnosed with hematologic cancers (90.3%), followed by bone and soft issue cancers (9.7%). Hematopoietic stem cell transplantation was part of cancer therapies for 5.5% survivors, and 42.4% received chemotherapy alone. The most commonly used anthracycline agent was doxorubicin (93.1%).</p><table-wrap position="float" id="cam46801-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Unadjusted and adjusted Cox proportional hazards models estimating time to initial cardiac test.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">Col.%</th><th align="left" valign="bottom" rowspan="1" colspan="1">Unadjusted HR (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;value</th><th align="left" valign="bottom" rowspan="1" colspan="1">Adjusted HR<xref rid="cam46801-note-0006" ref-type="table-fn">
<sup>d</sup>
</xref> (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;value</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="7" valign="top" rowspan="1">Sociodemographic characteristics</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" valign="top" rowspan="1">Age at index date<xref rid="cam46801-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">0&#8211;17&#8201;years</td><td align="left" valign="top" rowspan="1" colspan="1">831</td><td align="left" valign="top" rowspan="1" colspan="1">51.6</td><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">18&#8211;28&#8201;years</td><td align="left" valign="top" rowspan="1" colspan="1">778</td><td align="left" valign="top" rowspan="1" colspan="1">48.4</td><td align="left" valign="top" rowspan="1" colspan="1">0.44 (0.38, 0.52)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.42 (0.35, 0.49)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" valign="top" rowspan="1">Sex</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Male</td><td align="left" valign="top" rowspan="1" colspan="1">846</td><td align="left" valign="top" rowspan="1" colspan="1">52.6</td><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Female</td><td align="left" valign="top" rowspan="1" colspan="1">763</td><td align="left" valign="top" rowspan="1" colspan="1">47.4</td><td align="left" valign="top" rowspan="1" colspan="1">1.07 (0.93, 1.25)</td><td align="left" valign="top" rowspan="1" colspan="1">0.35</td><td align="left" valign="top" rowspan="1" colspan="1">0.99 (0.85, 1.15)</td><td align="left" valign="top" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" valign="top" rowspan="1">Geographic region</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Northeast</td><td align="left" valign="top" rowspan="1" colspan="1">376</td><td align="left" valign="top" rowspan="1" colspan="1">23.4</td><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">North central</td><td align="left" valign="top" rowspan="1" colspan="1">377</td><td align="left" valign="top" rowspan="1" colspan="1">23.4</td><td align="left" valign="top" rowspan="1" colspan="1">0.90 (0.73, 1.11)</td><td align="left" valign="top" rowspan="1" colspan="1">0.33</td><td align="left" valign="top" rowspan="1" colspan="1">0.98 (0.79, 1.21)</td><td align="left" valign="top" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">South</td><td align="left" valign="top" rowspan="1" colspan="1">558</td><td align="left" valign="top" rowspan="1" colspan="1">34.7</td><td align="left" valign="top" rowspan="1" colspan="1">0.82 (0.68, 1.00)</td><td align="left" valign="top" rowspan="1" colspan="1">0.051</td><td align="left" valign="top" rowspan="1" colspan="1">0.85 (0.70, 1.04)</td><td align="left" valign="top" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">West</td><td align="left" valign="top" rowspan="1" colspan="1">298</td><td align="left" valign="top" rowspan="1" colspan="1">18.5</td><td align="left" valign="top" rowspan="1" colspan="1">0.67 (0.53, 0.85)</td><td align="left" valign="top" rowspan="1" colspan="1">0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.71 (0.56, 0.90)</td><td align="left" valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" valign="top" rowspan="1">Rurality of residence</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Rural</td><td align="left" valign="top" rowspan="1" colspan="1">210</td><td align="left" valign="top" rowspan="1" colspan="1">13.1</td><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Urban</td><td align="left" valign="top" rowspan="1" colspan="1">1399</td><td align="left" valign="top" rowspan="1" colspan="1">86.9</td><td align="left" valign="top" rowspan="1" colspan="1">1.09 (0.87, 1.37)</td><td align="left" valign="top" rowspan="1" colspan="1">0.47</td><td align="left" valign="top" rowspan="1" colspan="1">1.10 (0.87, 1.39)</td><td align="left" valign="top" rowspan="1" colspan="1">0.43</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" valign="top" rowspan="1">Health plan type</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">High&#8208;deductible plan only</td><td align="left" valign="top" rowspan="1" colspan="1">219</td><td align="left" valign="top" rowspan="1" colspan="1">13.6</td><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Health maintenance organization only</td><td align="left" valign="top" rowspan="1" colspan="1">168</td><td align="left" valign="top" rowspan="1" colspan="1">10.4</td><td align="left" valign="top" rowspan="1" colspan="1">1.17 (0.87, 1.58)</td><td align="left" valign="top" rowspan="1" colspan="1">0.31</td><td align="left" valign="top" rowspan="1" colspan="1">1.19 (0.87, 1.62)</td><td align="left" valign="top" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Preferred provider organization only</td><td align="left" valign="top" rowspan="1" colspan="1">955</td><td align="left" valign="top" rowspan="1" colspan="1">59.4</td><td align="left" valign="top" rowspan="1" colspan="1">1.05 (0.83, 1.32)</td><td align="left" valign="top" rowspan="1" colspan="1">0.68</td><td align="left" valign="top" rowspan="1" colspan="1">1.07 (0.84, 1.35)</td><td align="left" valign="top" rowspan="1" colspan="1">0.59</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Other or multiple plan types</td><td align="left" valign="top" rowspan="1" colspan="1">267</td><td align="left" valign="top" rowspan="1" colspan="1">16.6</td><td align="left" valign="top" rowspan="1" colspan="1">1.10 (0.83, 1.45)</td><td align="left" valign="top" rowspan="1" colspan="1">0.50</td><td align="left" valign="top" rowspan="1" colspan="1">1.08 (0.81, 1.44)</td><td align="left" valign="top" rowspan="1" colspan="1">0.61</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" valign="top" rowspan="1">Year at index date<xref rid="cam46801-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">2009&#8211;2010</td><td align="left" valign="top" rowspan="1" colspan="1">171</td><td align="left" valign="top" rowspan="1" colspan="1">10.6</td><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">2011&#8211;2012</td><td align="left" valign="top" rowspan="1" colspan="1">416</td><td align="left" valign="top" rowspan="1" colspan="1">25.9</td><td align="left" valign="top" rowspan="1" colspan="1">0.82 (0.63, 1.05)</td><td align="left" valign="top" rowspan="1" colspan="1">0.12</td><td align="left" valign="top" rowspan="1" colspan="1">0.79 (0.61, 1.02)</td><td align="left" valign="top" rowspan="1" colspan="1">0.070</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">2013&#8211;2014</td><td align="left" valign="top" rowspan="1" colspan="1">431</td><td align="left" valign="top" rowspan="1" colspan="1">26.8</td><td align="left" valign="top" rowspan="1" colspan="1">0.91 (0.70, 1.17)</td><td align="left" valign="top" rowspan="1" colspan="1">0.44</td><td align="left" valign="top" rowspan="1" colspan="1">0.87 (0.67, 1.13)</td><td align="left" valign="top" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">2015&#8211;2016</td><td align="left" valign="top" rowspan="1" colspan="1">337</td><td align="left" valign="top" rowspan="1" colspan="1">20.9</td><td align="left" valign="top" rowspan="1" colspan="1">0.96 (0.74, 1.25)</td><td align="left" valign="top" rowspan="1" colspan="1">0.78</td><td align="left" valign="top" rowspan="1" colspan="1">0.84 (0.64, 1.10)</td><td align="left" valign="top" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">2017&#8211;2018</td><td align="left" valign="top" rowspan="1" colspan="1">254</td><td align="left" valign="top" rowspan="1" colspan="1">15.8</td><td align="left" valign="top" rowspan="1" colspan="1">0.93 (0.68, 1.25)</td><td align="left" valign="top" rowspan="1" colspan="1">0.61</td><td align="left" valign="top" rowspan="1" colspan="1">0.85 (0.62, 1.16)</td><td align="left" valign="top" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Clinical characteristics</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" valign="top" rowspan="1">Site and type of cancer</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Hematologic cancers<xref rid="cam46801-note-0004" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1453</td><td align="left" valign="top" rowspan="1" colspan="1">90.3</td><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Bone and soft tissue cancers</td><td align="left" valign="top" rowspan="1" colspan="1">156</td><td align="left" valign="top" rowspan="1" colspan="1">9.7</td><td align="left" valign="top" rowspan="1" colspan="1">1.84 (1.47, 2.29)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">1.64 (1.30, 2.07)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" valign="top" rowspan="1">Cancer treatment</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Chemotherapy only</td><td align="left" valign="top" rowspan="1" colspan="1">682</td><td align="left" valign="top" rowspan="1" colspan="1">42.4</td><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Any HSCT</td><td align="left" valign="top" rowspan="1" colspan="1">89</td><td align="left" valign="top" rowspan="1" colspan="1">5.5</td><td align="left" valign="top" rowspan="1" colspan="1">2.00 (1.49, 2.70)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">2.23 (1.63, 3.03)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Any radiation (no HSCT)</td><td align="left" valign="top" rowspan="1" colspan="1">475</td><td align="left" valign="top" rowspan="1" colspan="1">29.5</td><td align="left" valign="top" rowspan="1" colspan="1">1.17 (0.98, 1.40)</td><td align="left" valign="top" rowspan="1" colspan="1">0.09</td><td align="left" valign="top" rowspan="1" colspan="1">1.42 (1.18, 1.72)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Any surgery (no HSCT or radiation)</td><td align="left" valign="top" rowspan="1" colspan="1">363</td><td align="left" valign="top" rowspan="1" colspan="1">22.6</td><td align="left" valign="top" rowspan="1" colspan="1">1.10 (0.90, 1.34)</td><td align="left" valign="top" rowspan="1" colspan="1">0.36</td><td align="left" valign="top" rowspan="1" colspan="1">1.35 (1.09, 1.67)</td><td align="left" valign="top" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Receipt of any daunorubicin (ref: none)</td><td align="left" valign="top" rowspan="1" colspan="1">232</td><td align="left" valign="top" rowspan="1" colspan="1">14.4</td><td align="left" valign="top" rowspan="1" colspan="1">1.46 (1.21, 1.78)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">1.24 (0.97, 1.60)</td><td align="left" valign="top" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Receipt of any doxorubicin (ref: none)</td><td align="left" valign="top" rowspan="1" colspan="1">1498</td><td align="left" valign="top" rowspan="1" colspan="1">93.1</td><td align="left" valign="top" rowspan="1" colspan="1">0.68 (0.53, 0.89)</td><td align="left" valign="top" rowspan="1" colspan="1">0.005</td><td align="left" valign="top" rowspan="1" colspan="1">0.80 (0.56, 1.14)</td><td align="left" valign="top" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Receipt of other types of anthracycline<xref rid="cam46801-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref> (ref: none)</td><td align="left" valign="top" rowspan="1" colspan="1">32</td><td align="left" valign="top" rowspan="1" colspan="1">2.0</td><td align="left" valign="top" rowspan="1" colspan="1">0.93 (0.55, 1.58)</td><td align="left" valign="top" rowspan="1" colspan="1">0.78</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (0.56, 1.80)</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td></tr></tbody></table><table-wrap-foot id="cam46801-ntgp-0001"><fn id="cam46801-note-0001"><p>Abbreviations: CI, confidence interval; HSCT, hematopoietic stem cell transplantation; HR, hazard ratio; Ref, reference.</p></fn><fn id="cam46801-note-0002"><p>
<italic toggle="yes">Note</italic>: <italic toggle="yes">N</italic>&#8201;=&#8201;1609.</p></fn><fn id="cam46801-note-0003"><label>
<sup>a</sup>
</label><p>The index date was defined as 6&#8201;months after the end&#8208;of&#8208;therapy date.</p></fn><fn id="cam46801-note-0004"><label>
<sup>b</sup>
</label><p>Hematologic cancer includes leukemia and lymphoma. Using insurance claims data, our analysis relied on the International Classification of Diseases (ICD) diagnosis codes, which make it difficult to distinguish subtypes of hematological cancer.</p></fn><fn id="cam46801-note-0005"><label>
<sup>c</sup>
</label><p>Other types of anthracyclines include mitoxantrone, idarubicin, epirubicin, and alemtuzumab.</p></fn><fn id="cam46801-note-0006"><label>
<sup>d</sup>
</label><p>A multivariable Cox model was estimated that controlled for all covariates listed in this table.</p></fn></table-wrap-foot></table-wrap><p>Overall, the cumulative incidence of receiving an initial cardiac test by 5.25&#8201;years post index date was 62.3% (95% confidence interval [CI]: 57.5% to 66.7%), with median time to the initial test receipt being 2.7&#8201;years (95% CI: 2.5 to 3.1&#8201;years). Among cardiac test recipients (<italic toggle="yes">n</italic>&#8201;=&#8201;694 survivors), the vast majority underwent an echocardiogram (<italic toggle="yes">n</italic>&#8201;=&#8201;691 survivors). When stratified by age at index, the cumulative incidence of receiving an initial cardiac test within 5.25&#8201;years post index date remained lower in young adults than children &#8804;17&#8201;years (40.3% [95% CI: 34.2% to 46.4%] vs. 83.7% [95% CI: 76.6% to 88.8%]; Gray's test <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Figure&#160;<xref rid="cam46801-fig-0001" ref-type="fig">1</xref>). The cumulative incidence of receiving an initial cardiac test within 5.25&#8201;years post index date did not differ significantly by other sociodemographic characteristics, except for geographic region (Figure&#160;<xref rid="cam46801-supitem-0001" ref-type="supplementary-material">S2</xref>).</p><fig position="float" fig-type="FIGURE" id="cam46801-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Cumulative incidence curve of time to first cardiac test receipt after index date, by age group. The cumulative incidence of receiving the initial cardiac test (95% confidence interval) at 5.25&#8201;years post index date was 83.7% (76.6&#8211;88.8%) and 40.3% (34.2&#8211;46.4%) for children (&lt;18&#8201;years) and young adults (18&#8211;28&#8201;years), respectively (Gray's test <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="CAM4-12-22056-g001.jpg"/></fig><p>In the multivariable regression analysis, young adults were less likely to receive cardiac testing than children (hazard ratio [HR]&#8201;=&#8201;0.42; 95% CI: 0.35 to 0.49; Table&#160;<xref rid="cam46801-tbl-0001" ref-type="table">1</xref>). More likely to receive cardiac testing were survivors who underwent hematopoietic stem cell transplantation versus chemotherapy only (HR&#8201;=&#8201;2.23; 95% CI: 1.63 to 3.03), and survivors with bone and soft tissue cancers versus hematologic cancers (HR&#8201;=&#8201;1.64; 95% CI: 1.30 to 2.07). In addition, survivors living in the Western region were less likely than those in the Northeastern region to receive a cardiac test (HR&#8201;=&#8201;0.71; 95% CI: 0.56 to 0.90).</p></sec><sec sec-type="discussion" id="cam46801-sec-0004"><label>4</label><title>DISCUSSION</title><p>This nationwide, claims data&#8208;based study of a privately&#8208;insured cohort showed that nearly 40% of anthracycline&#8208;treated survivors of childhood and adolescent cancer at risk of cardiac dysfunction had not received any cardiac test within 5.25&#8201;years following index date, despite national guidelines during the study period detailing the importance of timely screening for early detection of cardiac dysfunction.<xref rid="cam46801-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="cam46801-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Our claims data provide precise measurement of realized cardiac testing and new evidence of age differences, with young adult survivors less likely than children to receive cardiac tests despite having insurance.</p><p>There are potential explanations for the low uptake of guideline&#8208;recommended cardiac testing. First, the transition into survivorship often involves primary care providers, who may not feel well&#8208;equipped to provide survivorship care or lack familiarity with the guidelines or survivors' therapy risk.<xref rid="cam46801-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="cam46801-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Inadequate care coordination between primary care providers and oncology specialists may exacerbate care fragmentation. Second, existing guidelines may be too complex to interpret and lack effective dissemination among providers who are not survivorship focused. Third, survivor&#8208;level challenges&#8212;including limited awareness of future health complications, limited knowledge and self&#8208;efficacy to pursue recommended testing and therapies, and logistical barriers including work limitations and travel time&#8212;may contribute to low uptake. The psychosocial effects of cancer&#8212;such as anxiety, depression, and financial hardship&#8212;may further deter survivorship care visits, particularly among young adults. Additionally, young adults face competing responsibilities (e.g., childcare, work schedule) that may limit attention to survivorship care. More research is needed to understand the multi&#8208;level causes of low uptake of cardiac testing, including challenges during young adults' transition from pediatric to adult care.</p><p>While our approach delineates feasibility of an algorithm for assessing specific screening service utilization in survivors of a childhood or adolescent cancer,<xref rid="cam46801-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> several study limitations are notable. First, the MarketScan&#174; database contains a convenience sample derived largely from medium&#8208;to&#8208;large employers<xref rid="cam46801-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="cam46801-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>; our findings may not generalize to other childhood and adolescent cancer&#8208;survivor populations in the United States. In particular, our sample could not capture those with public insurance such as Medicaid, the uninsured, and small employers, potentially underrepresenting survivors with lower socioeconomic status who may face additional barriers to accessing cardiac testing.<xref rid="cam46801-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="cam46801-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="cam46801-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> Second, these claims data do not provide the cumulative dose of anthracycline or capture tests self&#8208;paid or paid by public insurance. Similarly, our data lacked information on race and ethnicity.</p><p>Third, our claims&#8208;based analysis relied on ICD codes that were unable to clearly distinguish hematologic cancer subtypes. Fourth, to minimize sample attrition due to discontinued insurance enrollment over time, we did not assess long&#8208;term use of cardiac testing, an area meriting future investigation. In addition, we lacked information on whether survivors' discontinued enrollment was due to death. Since our model does not account for death as a competing risk, we might have overestimated test receipt rate.<xref rid="cam46801-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> However, sensitivity analysis using a subset of survivors with 5&#8208;year continuous enrollment showed results similar to our main analyses (results available upon request). Finally, as adult guidelines from the American Society of Clinical Oncology are discordant with the COG guidelines,<xref rid="cam46801-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> the recommended time to initiation of young adult cardiac testing remains ambiguous in the absence of symptoms or abnormal echocardiogram.</p><p>Our findings underscore the importance of future interventions to improve utilization of guideline&#8208;recommend cardiac tests among survivors of childhood and adolescent cancers. We demonstrate the feasibility of using insurance claims data to identify gaps in real&#8208;world cancer survivorship care. This approach informs future work to assess and implement guideline&#8208;recommended screening for late effects associated with therapies other than anthracycline.</p></sec><sec id="cam46801-sec-0010"><title>AUTHOR CONTRIBUTIONS</title><p>
<bold>Xu Ji:</bold> Conceptualization (equal); data curation (lead); funding acquisition (equal); investigation (equal); methodology (equal); project administration (equal); resources (lead); software (equal); validation (equal); visualization (supporting); writing &#8211; original draft (lead); writing &#8211; review and editing (equal). <bold>Xin Hu:</bold> Conceptualization (equal); formal analysis (lead); investigation (equal); methodology (equal); software (equal); validation (equal); visualization (lead); writing &#8211; review and editing (equal). <bold>Joseph Lipscomb:</bold> Conceptualization (equal); funding acquisition (equal); investigation (equal); methodology (equal); validation (equal); visualization (supporting); writing &#8211; review and editing (equal). <bold>Eric J. Chow:</bold> Conceptualization (equal); investigation (equal); methodology (equal); validation (equal); visualization (supporting); writing &#8211; review and editing (equal). <bold>Ann Mertens:</bold> Conceptualization (equal); funding acquisition (equal); investigation (equal); methodology (equal); supervision (equal); validation (equal); visualization (supporting); writing &#8211; review and editing (equal). <bold>Sharon Castellino:</bold> Conceptualization (equal); funding acquisition (equal); investigation (equal); methodology (equal); project administration (equal); supervision (equal); validation (equal); visualization (supporting); writing &#8211; review and editing (equal).</p></sec><sec id="cam46801-sec-0005"><title>FUNDING INFORMATION</title><p>This work was supported in part by a Pediatric Research Alliance Pilot Grant from the Pediatric Research Alliance and Children's Healthcare of Atlanta (Ji, Mertens, Castellino), and by Award SIP 20&#8211;004 from the Centers for Disease Control and Prevention (Ji, Lipscomb, Mertens, Castellino). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Centers for Disease Control and Prevention, the Pediatric Research Alliance, or Children's Healthcare of Atlanta.</p></sec><sec sec-type="COI-statement" id="cam46801-sec-0006"><title>CONFLICT OF INTEREST STATEMENT</title><p>Xu Ji, Sharon M. Castellino, Ann C. Mertens reported grants from the National Cancer Institute, National Institute on Minority Health and Health Disparities, Centers for Disease Control and Prevention, Emory University, Rally Foundation for Childhood Cancer Research, and The Leukemia &amp; Lymphoma Society outside the submitted work. Xin Hu received a predoctoral fellowship from the PhRMA Foundation outside the submitted work. The authors have no other conflicts of interest to disclose.</p></sec><sec id="cam46801-sec-0009"><title>ETHICS STATEMENT</title><p>This study was deemed exempt by the Emory University Institutional Review Board.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cam46801-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Data S1.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CAM4-12-22056-s001.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><sec sec-type="data-availability" id="cam46801-sec-0008"><title>DATA AVAILABILITY STATEMENT</title><p>Data for this analysis was made available to the authors through a third&#8208;party license from Merative, a commercial data provider in the United States. As such, the authors cannot make these data publicly available due to data use agreement. Other researchers can access the data by purchasing a license through Merative. The inclusion criteria specified in the Methods section would allow other researchers to identify the same cohort of patients used for this analysis. Interested individuals may visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://marketscan.truvenhealth.com/marketscanportal/" ext-link-type="uri" specific-use="software is-supplemented-by">https://marketscan.truvenhealth.com/marketscanportal/</ext-link> for more information on accessing Merative MarketScan databases.</p></sec><ref-list content-type="cited-references" id="cam46801-bibl-0001"><title>REFERENCES</title><ref id="cam46801-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cam46801-cit-0001"><string-name name-style="western"><surname>Robison</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Hudson</surname><given-names>MM</given-names></string-name>. <article-title>Survivors of childhood and adolescent cancer: life&#8208;long risks and responsibilities</article-title>. <source>Nat Rev Cancer</source>. <year>2014</year>;<volume>14</volume>(<issue>1</issue>):<fpage>61</fpage>&#8208;<lpage>70</lpage>.<pub-id pub-id-type="pmid">24304873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc3634</pub-id><pub-id pub-id-type="pmcid">PMC6425479</pub-id></mixed-citation></ref><ref id="cam46801-bib-0002"><label>2</label><mixed-citation publication-type="miscellaneous" id="cam46801-cit-0002"><collab collab-type="authors">Children's Oncology Group (COG)</collab>
. <article-title>Long&#8208;Term Follow&#8208;Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers</article-title>. <year>2018</year>. Children's Oncology Group Statistics and Data Center. Accessed February 1, 2022. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.survivorshipguidelines.org/pdf/2018/COG_LTFU_Guidelines_v5.pdf" ext-link-type="uri">http://www.survivorshipguidelines.org/pdf/2018/COG_LTFU_Guidelines_v5.pdf</ext-link></mixed-citation></ref><ref id="cam46801-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cam46801-cit-0003"><string-name name-style="western"><surname>Armenian</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Hudson</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Mulder</surname><given-names>RL</given-names></string-name>, et&#160;al. <article-title>Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the international late effects of childhood cancer guideline harmonization group</article-title>. <source>Lancet Oncol</source>. <year>2015</year>;<volume>16</volume>(<issue>3</issue>):<fpage>e123</fpage>&#8208;<lpage>e136</lpage>.<pub-id pub-id-type="pmid">25752563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(14)70409-7</pub-id><pub-id pub-id-type="pmcid">PMC4485458</pub-id></mixed-citation></ref><ref id="cam46801-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cam46801-cit-0004"><string-name name-style="western"><surname>Bates</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Howell</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Q</given-names></string-name>, et&#160;al. <article-title>Therapy&#8208;related cardiac risk in childhood cancer survivors: an analysis of the childhood cancer survivor study</article-title>. <source>J Clin Oncol</source>. <year>2019</year>;<volume>37</volume>(<issue>13</issue>):<fpage>1090</fpage>&#8208;<lpage>1101</lpage>.<pub-id pub-id-type="pmid">30860946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.18.01764</pub-id><pub-id pub-id-type="pmcid">PMC6494356</pub-id></mixed-citation></ref><ref id="cam46801-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cam46801-cit-0005"><string-name name-style="western"><surname>Marr</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Agha</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sutradhar</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Specialized survivor clinic attendance increases adherence to cardiomyopathy screening guidelines in adult survivors of childhood cancer</article-title>. <source>J Cancer Surviv</source>. <year>2017</year>;<volume>11</volume>(<issue>5</issue>):<fpage>614</fpage>&#8208;<lpage>623</lpage>.<pub-id pub-id-type="pmid">28785871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11764-017-0634-z</pub-id></mixed-citation></ref><ref id="cam46801-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cam46801-cit-0006"><string-name name-style="western"><surname>Yan</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <collab collab-type="authors">Henderson TO</collab>
, et&#160;al. <article-title>Adherence to surveillance for second malignant neoplasms and cardiac dysfunction in childhood cancer survivors: a childhood cancer survivor study</article-title>. <source>J Clin Oncol</source>. <year>2020</year>;<volume>38</volume>(<issue>15</issue>):<fpage>1711</fpage>&#8208;<lpage>1722</lpage>.<pub-id pub-id-type="pmid">32142393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.19.01825</pub-id><pub-id pub-id-type="pmcid">PMC7357338</pub-id></mixed-citation></ref><ref id="cam46801-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cam46801-cit-0007"><string-name name-style="western"><surname>Hudson</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Leisenring</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Stratton</surname><given-names>KK</given-names></string-name>, et&#160;al. <article-title>Increasing cardiomyopathy screening in at&#8208;risk adult survivors of pediatric malignancies: a randomized controlled trial</article-title>. <source>J Clin Oncol</source>. <year>2014</year>;<volume>32</volume>(<issue>35</issue>):<fpage>3974</fpage>&#8208;<lpage>3981</lpage>.<pub-id pub-id-type="pmid">25366684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2014.57.3493</pub-id><pub-id pub-id-type="pmcid">PMC4251960</pub-id></mixed-citation></ref><ref id="cam46801-bib-0008"><label>8</label><mixed-citation publication-type="miscellaneous" id="cam46801-cit-0008"><string-name name-style="western"><surname>Adamson</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hansen</surname><given-names>LG</given-names></string-name>. <article-title>Health Research Data for the Real World: The MarketScan Databases</article-title>. <year>2006</year>. Accessed December 7, 2019. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://patientprivacyrights.org/wp-content/uploads/2011/06/Thomson-Medstat-white-paper.pdf" ext-link-type="uri">http://patientprivacyrights.org/wp&#8208;content/uploads/2011/06/Thomson&#8208;Medstat&#8208;white&#8208;paper.pdf</ext-link></mixed-citation></ref><ref id="cam46801-bib-0009"><label>9</label><mixed-citation publication-type="miscellaneous" id="cam46801-cit-0009"><collab collab-type="authors">IBM Watson Health</collab>
. <article-title>IBM MarketScan Research Databases for life sciences researchers</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ibm.com/us-en/marketplace/marketscan-research-databases" ext-link-type="uri">https://www.ibm.com/us&#8208;en/marketplace/marketscan&#8208;research&#8208;databases</ext-link></mixed-citation></ref><ref id="cam46801-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cam46801-cit-0010"><string-name name-style="western"><surname>Ji</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Brock</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Mertens</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Cummings</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Effinger</surname><given-names>KE</given-names></string-name>. <article-title>Early Posttherapy opioid prescription, potential misuse, and substance use disorder among pediatric cancer survivors</article-title>. <source>J Natl Cancer Inst</source>. <year>2022</year>;<volume>114</volume>(<issue>6</issue>):<fpage>895</fpage>&#8208;<lpage>906</lpage>.<pub-id pub-id-type="pmid">35262708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djac049</pub-id><pub-id pub-id-type="pmcid">PMC9194632</pub-id></mixed-citation></ref><ref id="cam46801-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cam46801-cit-0011"><string-name name-style="western"><surname>Smitherman</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Mohabir</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wilkins</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Blatt</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Nichols</surname><given-names>HB</given-names></string-name>, <string-name name-style="western"><surname>Dusetzina</surname><given-names>SB</given-names></string-name>. <article-title>Early post&#8208;therapy prescription drug usage among childhood and adolescent cancer survivors</article-title>. <source>J Pediatr</source>. <year>2018</year>;<volume>195</volume>:<fpage>161</fpage>&#8208;<lpage>168.e7</lpage>.<pub-id pub-id-type="pmid">29395178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpeds.2017.11.063</pub-id><pub-id pub-id-type="pmcid">PMC5869116</pub-id></mixed-citation></ref><ref id="cam46801-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cam46801-cit-0012"><string-name name-style="western"><surname>Hu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Brock</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Effinger</surname><given-names>KE</given-names></string-name>, et&#160;al. <article-title>Changes in opioid prescriptions and potential misuse and substance use disorders among childhood cancer survivors following the 2016 opioid prescribing guideline</article-title>. <source>JAMA Oncol</source>. <year>2022</year>;<volume>8</volume>(<issue>11</issue>):<fpage>1658</fpage>&#8208;<lpage>1662</lpage>.<pub-id pub-id-type="pmid">36074473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2022.3744</pub-id><pub-id pub-id-type="pmcid">PMC9459898</pub-id></mixed-citation></ref><ref id="cam46801-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cam46801-cit-0013"><string-name name-style="western"><surname>Armenian</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bhatia</surname><given-names>S</given-names></string-name>. <article-title>Predicting and preventing anthracycline&#8208;related cardiotoxicity</article-title>. <source>Am Soc Clin Oncol Educ Book</source>. <year>2018</year>;<volume>38</volume>:<fpage>3</fpage>&#8208;<lpage>12</lpage>.<pub-id pub-id-type="pmid">30231396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/EDBK_100015</pub-id></mixed-citation></ref><ref id="cam46801-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cam46801-cit-0014"><string-name name-style="western"><surname>Lin</surname><given-names>DY</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Ying</surname><given-names>Z</given-names></string-name>. <article-title>Checking the Cox model with cumulative sums of martingale&#8208;based residuals</article-title>. <source>Biometrika</source>. <year>1993</year>;<volume>80</volume>(<issue>3</issue>):<fpage>557</fpage>&#8208;<lpage>572</lpage>.</mixed-citation></ref><ref id="cam46801-bib-0015"><label>15</label><mixed-citation publication-type="miscellaneous" id="cam46801-cit-0015"><collab collab-type="authors">Children's Oncology Group (COG)</collab>
. <article-title>Long&#8208;Term Follow&#8208;Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancer. Version 4.0</article-title>. <year>2013</year>. Children's Oncology Group Statistics and Data Center. Accessed September 7, 2019. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.survivorshipguidelines.org/pdf/COG%20LTFU%20Guidelines%20Archive/Version%204.0/COG_LTFU_Guidelines_v4%20(secured).pdf" ext-link-type="uri">http://www.survivorshipguidelines.org/pdf/COG%20LTFU%20Guidelines%20Archive/Version%204.0/COG_LTFU_Guidelines_v4%20(secured).pdf</ext-link></mixed-citation></ref><ref id="cam46801-bib-0016"><label>16</label><mixed-citation publication-type="miscellaneous" id="cam46801-cit-0016"><collab collab-type="authors">Children's Oncology Group (COG)</collab>
. <article-title>Long&#8208;Term Follow&#8208;Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Version 3.0</article-title>. <year>2008</year>. Children's Oncology Group Statistics and Data Center. Accessed January 20, 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://survivorshipguidelines.org/pdf/COG%20LTFU%20Guidelines%20Archive/Version%203.0/COG_LTFU_Guidelines_v3%20(secured).pdf" ext-link-type="uri">http://survivorshipguidelines.org/pdf/COG%20LTFU%20Guidelines%20Archive/Version%203.0/COG_LTFU_Guidelines_v3%20(secured).pdf</ext-link></mixed-citation></ref><ref id="cam46801-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cam46801-cit-0017"><string-name name-style="western"><surname>Signorelli</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wakefield</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Fardell</surname><given-names>JE</given-names></string-name>, et&#160;al. <article-title>The role of primary care physicians in childhood cancer survivorship care: multiperspective interviews</article-title>. <source>Oncologist</source>. <year>2019</year>;<volume>24</volume>(<issue>5</issue>):<fpage>710</fpage>&#8208;<lpage>719</lpage>.<pub-id pub-id-type="pmid">30171066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1634/theoncologist.2018-0103</pub-id><pub-id pub-id-type="pmcid">PMC6516111</pub-id></mixed-citation></ref><ref id="cam46801-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cam46801-cit-0018"><string-name name-style="western"><surname>Mertens</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Cotter</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Foster</surname><given-names>BM</given-names></string-name>, et&#160;al. <article-title>Improving health care for adult survivors of childhood cancer: recommendations from a delphi panel of health policy experts</article-title>. <source>Health Policy</source>. <year>2004</year>;<volume>69</volume>(<issue>2</issue>):<fpage>169</fpage>&#8208;<lpage>178</lpage>.<pub-id pub-id-type="pmid">15212864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.healthpol.2003.12.008</pub-id></mixed-citation></ref><ref id="cam46801-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cam46801-cit-0019"><string-name name-style="western"><surname>Ruddy</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Sangaralingham</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Van Houten</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Utilization of cardiac surveillance tests in survivors of breast cancer and lymphoma after anthracycline&#8208;based chemotherapy</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2020</year>;<volume>13</volume>(<issue>3</issue>):<elocation-id>e005984</elocation-id>.<pub-id pub-id-type="pmid">32106704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCOUTCOMES.119.005984</pub-id><pub-id pub-id-type="pmcid">PMC7101030</pub-id></mixed-citation></ref><ref id="cam46801-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cam46801-cit-0020"><string-name name-style="western"><surname>May</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Schwartz</surname><given-names>DD</given-names></string-name>, <string-name name-style="western"><surname>Frug&#233;</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Predictors of suboptimal follow&#8208;up in pediatric cancer survivors</article-title>. <source>J Pediatr Hematol Oncol</source>. <year>2017</year>;<volume>39</volume>(<issue>3</issue>):<fpage>e143</fpage>&#8208;<lpage>e149</lpage>.<pub-id pub-id-type="pmid">27984354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MPH.0000000000000723</pub-id></mixed-citation></ref><ref id="cam46801-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cam46801-cit-0021"><string-name name-style="western"><surname>Nathan</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Agha</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pole</surname><given-names>JD</given-names></string-name>, et&#160;al. <article-title>Predictors of attendance at specialized survivor clinics in a population&#8208;based cohort of adult survivors of childhood cancer</article-title>. <source>J Cancer Surviv</source>. <year>2016</year>;<volume>10</volume>(<issue>4</issue>):<fpage>611</fpage>&#8208;<lpage>618</lpage>.<pub-id pub-id-type="pmid">26868681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11764-016-0522-y</pub-id></mixed-citation></ref><ref id="cam46801-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cam46801-cit-0022"><string-name name-style="western"><surname>Zheng</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Sint</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Mitchell</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Kadan&#8208;Lottick</surname><given-names>NS</given-names></string-name>. <article-title>Patterns and predictors of survivorship clinic attendance in a population&#8208;based sample of pediatric and young adult childhood cancer survivors</article-title>. <source>J Cancer Surviv</source>. <year>2016</year>;<volume>10</volume>(<issue>3</issue>):<fpage>505</fpage>&#8208;<lpage>513</lpage>.<pub-id pub-id-type="pmid">26572903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11764-015-0493-4</pub-id></mixed-citation></ref><ref id="cam46801-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cam46801-cit-0023"><string-name name-style="western"><surname>Nolan</surname><given-names>EK</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>HY</given-names></string-name>. <article-title>A comparison of the Cox model to the fine&#8208;gray model for survival analyses of re&#8208;fracture rates</article-title>. <source>Arch Osteoporos</source>. <year>2020</year>;<volume>15</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>8</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11657-020-00748-x</pub-id><pub-id pub-id-type="pmid">32519193</pub-id></mixed-citation></ref><ref id="cam46801-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cam46801-cit-0024"><string-name name-style="western"><surname>Armenian</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Lacchetti</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Barac</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline</article-title>. <source>J Clin Oncol</source>. <year>2017</year>;<volume>35</volume>(<issue>8</issue>):<fpage>893</fpage>&#8208;<lpage>911</lpage>.<pub-id pub-id-type="pmid">27918725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2016.70.5400</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>